Skip to main content
Erschienen in:

09.02.2024 | Note

Angelica dahurica extract and its effective component bergapten alleviated hepatic fibrosis by activating FXR signaling pathway

verfasst von: Chong Gao, Zhong-He Hu, Zhen-Yu Cui, Yu-Chen Jiang, Jia-Yi Dou, Zhao-Xu Li, Li-Hua Lian, Ji-Xing Nan, Yan-Ling Wu

Erschienen in: Journal of Natural Medicines | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Angelica dahurica (A. dahurica) has a wide range of pharmacological effects, including analgesic, anti-inflammatory and hepatoprotective effects. In this study, we investigated the effect of A. dahurica extract (AD) and its effective component bergapten (BG) on hepatic fibrosis and potential mechanisms. Hepatic fibrosis was induced by intraperitoneal injection with carbon tetrachloride (CCl4) for 1 week, and mice were administrated with AD or BG by gavage for 1 week before CCl4 injection. Hepatic stellate cells (HSCs) were stimulated by transforming growth factor-β (TGF-β) and cultured with AD, BG, GW4064 (FXR agonist) or Guggulsterone (FXR inhibitor). In CCl4-induced mice, AD significantly decreased serum aminotransferase, reduced excess accumulation of extracellular matrix (ECM), inhibited caspase-1 and IL-1β, and increased FXR expressions. In activated HSCs, AD suppressed the expressions of α-SMA, collagen I, and TIMP-1/MMP-13 ratio and inflammatory factors, functioning as FXR agonist. In CCl4-induced mice, BG significantly improved serum transaminase and histopathological changes, reduced ECM excessive deposition, inflammatory response, and activated FXR expression. BG increased FXR expression and inhibited α-SMA and IL-1β expressions in activated HSCs, functioning as GW4064. FXR deficiency significantly attenuated the decreasing effect of BG on α-SMA and IL-1β expressions in LX-2 cells. In conclusion, AD could regulate hepatic fibrosis by regulating ECM excessive deposition and inflammation. Activating FXR signaling by BG might be the potential mechanism of AD against hepatic fibrosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18:151–166CrossRefPubMed Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18:151–166CrossRefPubMed
2.
Zurück zum Zitat Mu M, Zuo S, Wu RM, Deng KS, Lu S, Zhu JJ, Zou G, Yang J, Cheng ML, Zhao XK (2018) Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway. Drug Des Devel Ther 12:4107–4115CrossRefPubMedPubMedCentral Mu M, Zuo S, Wu RM, Deng KS, Lu S, Zhu JJ, Zou G, Yang J, Cheng ML, Zhao XK (2018) Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway. Drug Des Devel Ther 12:4107–4115CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat He X, Chen J, Mu Y, Zhang H, Chen G, Liu P, Liu W (2020) The effects of inhibiting the activation of hepatic stellate cells by lignan components from the fruits of Schisandra chinensis and the mechanism of schisanhenol. J Nat Med 74:513–524CrossRefPubMed He X, Chen J, Mu Y, Zhang H, Chen G, Liu P, Liu W (2020) The effects of inhibiting the activation of hepatic stellate cells by lignan components from the fruits of Schisandra chinensis and the mechanism of schisanhenol. J Nat Med 74:513–524CrossRefPubMed
4.
Zurück zum Zitat Liu X, Xu J, Brenner DA, Kisseleva T (2013) Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 1:209–214CrossRefPubMedPubMedCentral Liu X, Xu J, Brenner DA, Kisseleva T (2013) Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 1:209–214CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Parola M, Pinzani M (2019) Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37–55CrossRefPubMed Parola M, Pinzani M (2019) Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37–55CrossRefPubMed
7.
Zurück zum Zitat Yang D, Li L, Qian S, Liu L (2018) Evodiamine ameliorates liver fibrosis in rats via TGF-β1/Smad signaling pathway. J Nat Med 72:145–154CrossRefPubMed Yang D, Li L, Qian S, Liu L (2018) Evodiamine ameliorates liver fibrosis in rats via TGF-β1/Smad signaling pathway. J Nat Med 72:145–154CrossRefPubMed
9.
Zurück zum Zitat Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397–411CrossRefPubMed Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397–411CrossRefPubMed
10.
11.
Zurück zum Zitat Dooley S, ten Dijke P (2019) TGF-β in progression of liver disease. Cell Tissue Res 347:245–256CrossRef Dooley S, ten Dijke P (2019) TGF-β in progression of liver disease. Cell Tissue Res 347:245–256CrossRef
12.
Zurück zum Zitat Xu A, Li Y, Zhao W, Hou F, Li X, Sun L, Chen W, Yang A, Wu S, Zhang B, Yao J, Wang H, Huang J (2018) PHP14 regulates hepatic stellate cells migration in liver fibrosis via mediating TGF-β1 signaling to PI3Kγ/AKT/Rac1 pathway. J Mol Med (Berl) 96:119–133CrossRefPubMed Xu A, Li Y, Zhao W, Hou F, Li X, Sun L, Chen W, Yang A, Wu S, Zhang B, Yao J, Wang H, Huang J (2018) PHP14 regulates hepatic stellate cells migration in liver fibrosis via mediating TGF-β1 signaling to PI3Kγ/AKT/Rac1 pathway. J Mol Med (Berl) 96:119–133CrossRefPubMed
13.
Zurück zum Zitat Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N (2018) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101ADSCrossRef Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N (2018) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101ADSCrossRef
14.
Zurück zum Zitat Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, Bhasin K, Jones BA, Orlicky DJ, Takahashi S, Dvornikov A, Kleiner DE, Hewitt SM, Adorini L, Kopp JB, Krausz KW, Rosenberg A, McManaman JL, Robertson CE, Ir D, Frank DN, Luo Y, Gonzalez FJ, Gratton E, Levi M (2022) The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem 298:102530CrossRefPubMedPubMedCentral Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, Bhasin K, Jones BA, Orlicky DJ, Takahashi S, Dvornikov A, Kleiner DE, Hewitt SM, Adorini L, Kopp JB, Krausz KW, Rosenberg A, McManaman JL, Robertson CE, Ir D, Frank DN, Luo Y, Gonzalez FJ, Gratton E, Levi M (2022) The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem 298:102530CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678–1687CrossRefPubMedPubMedCentral Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678–1687CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Tian SY, Chen SM, Pan CX, Li Y (2022) FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin 43:1120–1132CrossRefPubMedPubMedCentral Tian SY, Chen SM, Pan CX, Li Y (2022) FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin 43:1120–1132CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Halilbasic E, Fuchs C, Traussnigg S, Trauner M (2022) Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease. Dig Dis 34:580–588CrossRef Halilbasic E, Fuchs C, Traussnigg S, Trauner M (2022) Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease. Dig Dis 34:580–588CrossRef
18.
Zurück zum Zitat Han X, Cui ZY, Song J, Piao HQ, Lian LH, Hou LS, Wang G, Zheng S, Dong XX, Nan JX, Wu YL (2019) Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact 311:108794CrossRefPubMed Han X, Cui ZY, Song J, Piao HQ, Lian LH, Hou LS, Wang G, Zheng S, Dong XX, Nan JX, Wu YL (2019) Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact 311:108794CrossRefPubMed
19.
Zurück zum Zitat Zhao H, Feng YL, Wang M, Wang JJ, Liu T, Yu J (2022) The Angelica dahurica: a review of traditional uses. Phytochemistry and Pharmacology Front Pharmacol 13:896637CrossRefPubMed Zhao H, Feng YL, Wang M, Wang JJ, Liu T, Yu J (2022) The Angelica dahurica: a review of traditional uses. Phytochemistry and Pharmacology Front Pharmacol 13:896637CrossRefPubMed
20.
Zurück zum Zitat Liang WH, Chang TW, Charng YC (2018) Effects of drying methods on contents of bioactive compounds and antioxidant activities of Angelica dahurica. Food Sci Biotechnol 27:1085–1092CrossRefPubMedPubMedCentral Liang WH, Chang TW, Charng YC (2018) Effects of drying methods on contents of bioactive compounds and antioxidant activities of Angelica dahurica. Food Sci Biotechnol 27:1085–1092CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Liang Y, Xie L, Liu K, Cao Y, Dai X, Wang X, Lu J, Zhang X, Li X (2021) Bergapten: a review of its pharmacology, pharmacokinetics, and toxicity. Phytother Res 35:6131–6147CrossRefPubMed Liang Y, Xie L, Liu K, Cao Y, Dai X, Wang X, Lu J, Zhang X, Li X (2021) Bergapten: a review of its pharmacology, pharmacokinetics, and toxicity. Phytother Res 35:6131–6147CrossRefPubMed
22.
Zurück zum Zitat Quetglas-Llabrés MM, Quispe C, Herrera-Bravo J, Catarino MD, Pereira OR, Cardoso SM, Dua K, Chellappan DK, Pabreja K, Satija S, Mehta M, Sureda A, Martorell M, Satmbekova D, Yeskaliyeva B, Sharifi-Rad J, Rasool N, Butnariu M, Bagiu IC, Bagiu RV, Calina D, Cho WC (2022) Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev 2022:8615242CrossRefPubMedPubMedCentral Quetglas-Llabrés MM, Quispe C, Herrera-Bravo J, Catarino MD, Pereira OR, Cardoso SM, Dua K, Chellappan DK, Pabreja K, Satija S, Mehta M, Sureda A, Martorell M, Satmbekova D, Yeskaliyeva B, Sharifi-Rad J, Rasool N, Butnariu M, Bagiu IC, Bagiu RV, Calina D, Cho WC (2022) Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev 2022:8615242CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Liu WX, Jia FL, He YY, Zhang BX (2012) Protective effects of 5-methoxypsoralen against acetaminophen-induced hepatotoxicity in mice. World J Gastroenterol 18:2197–2202CrossRefPubMedPubMedCentral Liu WX, Jia FL, He YY, Zhang BX (2012) Protective effects of 5-methoxypsoralen against acetaminophen-induced hepatotoxicity in mice. World J Gastroenterol 18:2197–2202CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Wan P, Hengfan NI, Dale G, Yun D, Manyun D (2023) Farnesoid X receptor regulators from natural products and their biological function. J Tradit Chin Med 43:618–626PubMed Wan P, Hengfan NI, Dale G, Yun D, Manyun D (2023) Farnesoid X receptor regulators from natural products and their biological function. J Tradit Chin Med 43:618–626PubMed
25.
Zurück zum Zitat Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F (2021) Cellular and molecular mechanisms underlying liver fibrosis regression. Cells 10(10):2759CrossRefPubMedPubMedCentral Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F (2021) Cellular and molecular mechanisms underlying liver fibrosis regression. Cells 10(10):2759CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, Hu YY, Liu P, Su SB (2016) Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. J Toxicol Sci 41:561–572CrossRefPubMed Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, Hu YY, Liu P, Su SB (2016) Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. J Toxicol Sci 41:561–572CrossRefPubMed
27.
Zurück zum Zitat Kong D, Zhang F, Zhang Z, Lu Y, Zheng S (2013) Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 67:246–250CrossRefPubMed Kong D, Zhang F, Zhang Z, Lu Y, Zheng S (2013) Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 67:246–250CrossRefPubMed
28.
Zurück zum Zitat Wree A, Holtmann TM, Inzaugarat ME, Feldstein AE (2019) Novel drivers of the inflammatory response in liver injury and fibrosis. Semin Liver Dis 39:275–282CrossRefPubMed Wree A, Holtmann TM, Inzaugarat ME, Feldstein AE (2019) Novel drivers of the inflammatory response in liver injury and fibrosis. Semin Liver Dis 39:275–282CrossRefPubMed
29.
Zurück zum Zitat Gong J, Yang F, Yang Q, Tang X, Shu F, Xu L, Wang Z, Yang L (2020) Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway. J Nat Med 74:17–25CrossRefPubMed Gong J, Yang F, Yang Q, Tang X, Shu F, Xu L, Wang Z, Yang L (2020) Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway. J Nat Med 74:17–25CrossRefPubMed
30.
Zurück zum Zitat Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H (2022) Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian J Gastroenterol 41:169–180CrossRefPubMed Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H (2022) Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian J Gastroenterol 41:169–180CrossRefPubMed
31.
Zurück zum Zitat Song J, Cui ZY, Lian LH, Han X, Hou LS, Wang G, Gao L, Zhu Y, Jiang YC, Dou JY, Hu ZH, Zhao YQ, Nan JX, Wu YL (2020) 20S-Protopanaxatriol ameliorates hepatic fibrosis, potentially involving FXR-mediated inflammatory signaling cascades. J Agric Food 68:8195–8204CrossRef Song J, Cui ZY, Lian LH, Han X, Hou LS, Wang G, Gao L, Zhu Y, Jiang YC, Dou JY, Hu ZH, Zhao YQ, Nan JX, Wu YL (2020) 20S-Protopanaxatriol ameliorates hepatic fibrosis, potentially involving FXR-mediated inflammatory signaling cascades. J Agric Food 68:8195–8204CrossRef
32.
Zurück zum Zitat Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W (2016) FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6:33453ADSCrossRefPubMedPubMedCentral Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W (2016) FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6:33453ADSCrossRefPubMedPubMedCentral
Metadaten
Titel
Angelica dahurica extract and its effective component bergapten alleviated hepatic fibrosis by activating FXR signaling pathway
verfasst von
Chong Gao
Zhong-He Hu
Zhen-Yu Cui
Yu-Chen Jiang
Jia-Yi Dou
Zhao-Xu Li
Li-Hua Lian
Ji-Xing Nan
Yan-Ling Wu
Publikationsdatum
09.02.2024
Verlag
Springer Nature Singapore
Erschienen in
Journal of Natural Medicines / Ausgabe 2/2024
Print ISSN: 1340-3443
Elektronische ISSN: 1861-0293
DOI
https://doi.org/10.1007/s11418-024-01780-8